Hussein A. Tawbi

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0003-1942-851X

MedicineImmunology and MicrobiologyBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Papers

Driven by 45 papers — median percentile 0. Top paper: “Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)”.

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

Neuro-Oncology(2021)10.1093/neuonc/noab094

N/A

4.0DataRank · unranked

126 citations

Peter Forsyth, F. Stephen Hodi, Christopher D. Lao, Stergios J. Moschos, Omid Hamid +18 more

Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions

Neuro-Oncology(2022)10.1093/neuonc/noac118

N/A

3.5DataRank · unranked

197 citations

Nayan Lamba, Manmeet S. Ahluwalia, Kenneth Aldape, Adrienne Boire, Priscilla K. Brastianos +20 more

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

Nature Medicine(2023)10.1038/s41591-022-02170-x

N/A

1.9DataRank · unranked

83 citations

Sherise D. Ferguson, Roland L. Bassett, Alexandra P. Foster, Ida John, Tarin Hennegan +32 more

Leptomeningeal disease in melanoma patients: An update to treatment, challenges, and future directions

Pigment Cell & Melanoma Research(2020)10.1111/pcmr.12861

N/A

1.6DataRank · unranked

57 citations

Keiran S.M. Smalley, Priscilla K. Brastianos, Michael A. Davies, Ian E. McCutcheon, James K. Liu +13 more

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Science(2018)10.1126/science.aan4236

N/A

1.3DataRank · unranked

4585 citations

C. N. Spencer, Luigi Nezi, Alexandre Reuben, Miles C. Andrews, Tatiana V. Karpinets +89 more

B cells are associated with survival and immunotherapy response in sarcoma

Nature(2020)10.1038/s41586-019-1906-8

N/A

1.1DataRank · unranked

1962 citations

Aurélien de Reyniès, Emily Z. Keung, Tom Wei‐Wu Chen, Cheng‐Ming Sun, Julien Caldéraro +24 more

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

New England Journal of Medicine(2018)10.1056/nejmoa1805453

N/A

1.1DataRank · unranked

1335 citations

Peter A. Forsyth, Alain Algazi, Omid Hamid, F. Stephen Hodi, Stergios J. Moschos +17 more

National Cancer Institute Collaborative Workshop on Shaping the Landscape of Brain Metastases Research: challenges and recommended priorities

The Lancet Oncology(2023)10.1016/s1470-2045(23)00297-8

N/A

1.1DataRank · unranked

39 citations

Minesh P. Mehta, Dee Dee Smart, Patricia S. Steeg, Julie A. Hong, Michael Graham Espey +39 more

Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade

Nature Medicine(2021)10.1038/s41591-021-01406-6

N/A

0.910DataRank · unranked

429 citations

Connie P. M. Duong, Vancheswaran Gopalakrishnan, Valerio Iebba, W. S. Chen, Lisa Derosa +66 more

Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and clinical benefit

Cancer(2021)10.1002/cncr.34004

N/A

0.890DataRank · unranked

21 citations

Sahira Farooq, Macartney Welborn, Rodabe N. Amaria, Susan Y. Chon, Adi Diab +13 more

Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2022)10.1038/s41586-022-05368-8

N/A

0.874DataRank · unranked

339 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-19-1824

N/A

0.807DataRank · unranked

216 citations

Melissa Burgess, Ruth Salazar, Edwin R. Parra, Jaime Rodrigues-Canales, Vanessa Bolejack +18 more

Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy

Nature(2022)10.1038/s41586-022-04833-8

N/A

0.731DataRank · unranked

130 citations

Michael G. White, Miles C. Andrews, Manoj Chelvanambi, Russell G. Witt, Joseph R. Daniele +60 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0.716DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

The State of Melanoma: Emergent Challenges and Opportunities

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4092

N/A

0.705DataRank · unranked

109 citations

Clara Curiel‐Lewandrowski, David E. Fisher, Susan M. Swetter, Hensin Tsao, Julio A. Aguirre‐Ghiso +31 more

Trametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2

JCO Precision Oncology(2023)10.1200/po.22.00421

N/A

0.656DataRank · unranked

16 citations

Yael Flamand, Melissa Wilson, Jason J. Luke, Hussein A. Tawbi, Fangxin Hong +19 more

Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-2581

N/A

0.636DataRank · unranked

17 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047

Journal of Clinical Oncology(2025)10.1200/jco.24.01124

N/A

0.633DataRank · unranked

67 citations

F. Stephen Hodi, Evan J. Lipson, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala +14 more

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer

ESMO Open(2025)10.1016/j.esmoop.2025.104536

N/A

0.626DataRank · unranked

64 citations

Martin H. Voss, Hussein A. Tawbi, Michael S. Gordon, Scott S. Tykodi, Elaine T. Lam +13 more

A randomized, non-comparative phase 2 study of neoadjuvant immune-checkpoint blockade in retroperitoneal dedifferentiated liposarcoma and extremity/truncal undifferentiated pleomorphic sarcoma

Nature Cancer(2024)10.1038/s43018-024-00726-z

N/A

0.612DataRank · unranked

58 citations

Elise F. Nassif, Emily Z. Keung, Wei‐Lien Wang, Alexander J. Lazar, Heather Lin +54 more

A mathematical model for the quantification of a patient’s sensitivity to checkpoint inhibitors and long-term tumour burden

Nature Biomedical Engineering(2021)10.1038/s41551-020-00662-0

N/A

0.587DataRank · unranked

49 citations

Zhihui Wang, Dalia Elganainy, Karine A. Al Feghali, Marija Plodinec, George A. Calin +11 more

Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

Journal for ImmunoTherapy of Cancer(2021)10.1136/jitc-2021-002449

N/A

0.574DataRank · unranked

45 citations

Rodabe N. Amaria, Amer Najjar, Laszlo Radvanyi, Cara Haymaker, Marie-Andrée Forget +18 more

Histopathological features of complete pathological response predict recurrence-free survival following neoadjuvant targeted therapy for metastatic melanoma

Annals of Oncology(2020)10.1016/j.annonc.2020.07.016

N/A

0.538DataRank · unranked

35 citations

Chandra Mani Adhikari, Serigne Lo, Robert V. Rawson, Rodabe N. Amaria, Alexander M. Menzies +16 more

Current drug development and trial designs in neuro-oncology: report from the first American Society of Clinical Oncology and Society for Neuro-Oncology Clinical Trials Conference

The Lancet Oncology(2023)10.1016/s1470-2045(23)00005-0

N/A

0.494DataRank · unranked

26 citations

Mei‐Yin C. Polley, Laura Alder, Priscilla K. Brastianos, Carey K. Anders, Hussein A. Tawbi +9 more

A phase 1 study of NY-ESO-1 vaccine + anti-CTLA4 antibody Ipilimumab (IPI) in patients with unresectable or metastatic melanoma

OncoImmunology(2021)10.1080/2162402x.2021.1898105

N/A

0.489DataRank · unranked

25 citations

Hassane M. Zarour, Hussein A. Tawbi, John M. Kirkwood, Michael A. Postow, Philip Friedlander +11 more

Melanoma central nervous system metastases: An update to approaches, challenges, and opportunities

Pigment Cell & Melanoma Research(2022)10.1111/pcmr.13059

N/A

0.425DataRank · unranked

16 citations

Maya Dimitrova, Kevin Kleffman, Christopher Alvarez‐Breckenridge, Michael B. Atkins, Adrienne Boire +22 more

Molecular and immunological associations of elevated serum lactate dehydrogenase in metastatic melanoma patients: A fresh look at an old biomarker

Cancer Medicine(2020)10.1002/cam4.3474

N/A

0.425DataRank · unranked

16 citations

Fernando C. L. Carapeto, Aron Y. Joon, Lauren E. Haydu, Huiqin Chen, Fuchenchu Wang +13 more

Identification of MicroRNA–mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes

Cancers(2021)10.3390/cancers13215301

N/A

0.385DataRank · unranked

12 citations

Michael G. White, Russell G. Witt, Anik Banerjee, Michael A. Davies, Guangchun Han +18 more

Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf -mutated melanoma

OncoImmunology(2021)10.1080/2162402x.2021.1992880

N/A

0.385DataRank · unranked

12 citations

Robert Szczepaniak‐Sloane, Russell G. Witt, Alexandre Reuben, Pierre Olivier Gaudreau, Miles C. Andrews +27 more

Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19

Cancers(2022)10.3390/cancers15010275

N/A

0.373DataRank · unranked

11 citations

Divya Yadav, Lingzhi Hong, Elliana Young, Paul Edelkamp, Maliazurina B. Saad +23 more

The evolving landscape of brain metastasis: volume II

Trends in cancer(2025)10.1016/j.trecan.2025.11.007

N/A

0.349DataRank · unranked

9 citations

Carey K. Anders, Adrienne Boire, Benjamin Izar, Nuria Kotecki, Srinivas Malladi +12 more

Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma

OncoImmunology(2025)10.1080/2162402x.2025.2546402

N/A

0.323DataRank · unranked

7 citations

Simin Kiany, Marie‐Andrée Forget, Roland L. Bassett, Michael A. Davies, Adi Diab +15 more

SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-3882

N/A

0.208DataRank · unranked

3 citations

Elina Mukherjee, David Ferraro, Shanthi Bhaskar, Anthony Green, E. Michael Meyer +6 more

Safety and preliminary efficacy of intrathecal (IT) and intravenous (IV) nivolumab (N) for patients (pts) with leptomeningeal disease (LMD).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.9554

N/A

0.174DataRank · unranked

2 citations

Ida John, Suzanne Phillips, Lauren See, Roland L. Bassett, Ruitao Lin +15 more

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

Nature(2023)10.1038/s41586-023-05892-1

N/A

0.165DataRank · unranked

2 citations

Michael A. Postow, Elizabeth M. Burton, Michael T. Tetzlaff, Merrick I. Ross, Carlos A. Torres‐Cabala +35 more

Longitudinal single-cell (sc) immune profiling of cerebrospinal fluid (CSF) from melanoma patients (pts) with leptomeningeal disease (LMD) treated with intrathecal (IT) and intravenous (IV) nivolumab (N).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.2015

N/A

0.113DataRank · unranked

1 citations

Yitao Yang, Sheila Duncan, Sherise D. Ferguson, Jennifer A. Wargo, Elizabeth M. Burton +5 more

Changes in outcomes and factors associated with survival in melanoma patients with brain metastases

Neuro-Oncology(2022)10.1093/neuonc/noac251

N/A

0DataRank · unranked

22 citations

Denái R. Milton, Alicia Bea Davies, Elizabeth Sirmans, Chantal Saberian, Eliza Posada +22 more

“Liquid Gold” - The unTAPped Potential of Cerebrospinal Fluid Analysis?

Clinical Cancer Research(2020)10.1158/1078-0432.ccr-20-0173

N/A

0DataRank · unranked

1 citations

Hussein A. Tawbi, I. C. Glitza

Androgen receptor activity promotes resistance to BRAF-targeted melanoma therapy

Research Square(2020)10.21203/rs.3.rs-58480/v1

N/A

0DataRank · unranked

0 citations

Christopher P. Vellano, Michael White, Miles C. Andrews, Joseph R. Daniele, Mark Titus +41 more

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study

Cancers(2023)10.3390/cancers15102690

N/A

0DataRank · unranked

6 citations

Gabrielle F. Duhon, Juan Ignacio Ruiz, Mehmet Altan, Hussein A. Tawbi, Adi Diab +6 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Data from Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases

(2023)10.1158/1078-0432.c.6533110.v1

Top 100%

0DataRank

Top 100%0 citations

Hussein A. Tawbi, Johnathan A. Engh, Nduka Amankulor, Brindha Shivalingam, Hiya Banerjee +13 more

Immune-related adverse events and symptom burden in patients with melanoma receiving adjuvant immune checkpoint inhibitor.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps12147

N/A

0DataRank · unranked

0 citations

Teresa Kuś, Salah-Eddine Bentebibel, Jennifer L. McQuade, Isabella Claudia Glitza, Rodabe N. Amaria +11 more

Consortium for Intracranial Metastasis Academic Research (CIMARa): Global interdisciplinary collaborations to improve outcomes of patients with brain metastases

Neuro-Oncology Advances(2025)10.1093/noajnl/vdaf049

N/A

0DataRank · unranked

2 citations

Amanda E.D. Van Swearingen, Josh Neman, Johanna A. Joyce, Diana M. Cittelly, Manuel Valiente +17 more

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson’s disease

npj Parkinson s Disease(2025)10.1038/s41531-025-01215-5

N/A

0DataRank · unranked

1 citations

Yuhang Zhao, Sarfraz Ahmed, Jackson G. Schumacher, Jae Suk Ahn, L Shi +10 more

Hussein A. Tawbi

Indexed papers

Top data-sharing exemplar

Papers